Log in using OpenID

Global Bispecific Antibodies Market Industry Insights 2024

In Europe and North America, incidence of diseases such as lung cancer, cervical cancer, breast cancer, and prostate cancer is increasing, with the regions accounting for the highest incidence rate for these diseases worldwide. Moreover, with these
Artificial Pancreas Market Industry
Bispecific Antibodies Market – Global Industry
Insights, Trends and Opportunity Analysis, 20162024
[Company address]
Report Description
Key players involved in the Bispecific antibodies market include
Some of the key players in Bispecific antibodies market are Amgen, Inc., Bayer AG, Dow Pharmaceutical
Solutions, ImmunGene, Inc., Immunocore Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and F.
Hoffmann-La Roche AG.
Bispecific Antibodies Market Overview
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal
antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most
widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications
of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it.
Bispecific antibodies are emerging a technologically advanced solution for dual targeting strategies wi thin
same molecule.
Due to its dual specificity, bispecific antibody can aid in redirecting T cells to tumor cells, blocking two
different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering
payloads to targeted sites. Catumaxomab and blinatumomab are the two U.S. FDA approved bispecific
antibody products, which would fuel growth of the bispecific antibodies market. Bispecific antibodies can
be divided into three main classes namely, fragment, symmetric, and asymmetric antibodies. Fragment
bispecific antibodies such as a nanobody DART and BiTE are currently undergoing clinical trials. Likewise,
tetravalent BsAb - DVD and DAF symmetric antibodies are under research. Companies such as Sanofi
S.A., Merck & Co., Inc. and Genentech, Inc. are conducting research on symmetric bispecific antibodies.
BEAT, duobody, and crossmab are examples of asymmetric bispecific antibodies, which are currently
being researched by Glenmark Pharmaceuticals, Eli Lilly and Company, and Genmab A/S.
Get Free Sample Report:
Catumaxomab – the first Bispecific antibody boost growth of the bispecific antibodies market
As of 2015, over 60 different BsAb formats have been developed, with some making their way into the
clinical trials. Bispecific antibodies market growth is increasing due to the limitation of monoclonal
antibodies in drug resistance and failure to respond in treatment. Hence, the bispecific antibodies market
is projected to gain significant growth traction in the near future.
Catumaxomab is a rat – mouse hybrid monoclonal bispecific trifunctional antibody used to treat malignant
ascites. It was developed by Fresenius Biotech and Trion Pharma. Catumaxomab was approved in
Europe in 2009 and is undergoing clinical trials in the U.S. Sold under the brand name Removab,
Catumaxomab is administered to patients with EpCAM-poisitve carcinoma.
North America and Europe are major regions for Bispecific antibodies market
In Europe and North America, incidence of diseases such as lung cancer, cervical cancer, breast cancer,
and prostate cancer is increasing, with the regions accounting for the highest incidence rate for these
diseases worldwide. Moreover, with these regions being home to major players, these are the largest
bispecific antibodies market. Supportive government initiatives are further fueling growth of bispecific
antibody treatment markets in North America and Europe. Increasing healthcare access and awareness
in developing regions such as Asia Pacific, Latin America, and Middle East are projected to propel demand
for BsAb owing to fuel growth of the bispecific antibodies market in the near future.
View the Full Report:
Increasing investments to harness the potential of highly effective BsAb Drug Therapy
Various pharmaceutical companies are actively involved in development and manufacture of bispecific
antibodies. MedImmune, LLC and Abpro, collaborated in December 2016 to develop novel bispecific
antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor. Government
funding is projected to further encourage research and development in this field.
About Us
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting
our plethora of clients achieve transformational growth by helping them make critical business decisions.
We are headquartered in India, having office at global financial capital in the U.S. Our client base includes
players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to
help businesses around the globe deliver practical and lasting results through various recommendations
about operational improvements, technologies, emerging market trends and new working methods. We
offer both customized and syndicated market research reports that help our clients create visionary growth
plans to provide traction to their business. We meticulously study emerging trends across various
industries at both the global and regional levels to identify new opportunities for our clientele. Our global
team of over 100 research analysts and freelance consultants provide market intelligence from the very
molecular country level and also provide a global perspective of the market. Our team is of the most vital
cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive
defusion training module.This allows for an objective and unbiased assessment of the market. We pride
ourselves in my constantly striving to update our extremely in-depth understanding of the market by
closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable
industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize
on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth
path in the future.
Contact Us
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel No: (+1)206-701-6702
Email: [email protected]
Visit Blog:
Report inappropriate content